Nektar Therapeutics holds $953M in cash and investments
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Nektar Therapeutics (NKTR) reported $952.9 million in cash and investments in marketable securities as of September 30, 2026. Consistent with its prior guidance, the company expects this cash balance to extend its runway into the third quarter of 2028, past the initial data readouts from its Phase 3 ZENITH AD trials in atopic dermatitis in summer 2028.
8-K Event Classification
Item 7.01 — Regulation FD Disclosure
1 item
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Key Figures
Cash and investments in marketable securities: $952.9 million
Expected cash runway: Into the third quarter of 2028
Initial ZENITH AD trial data readouts: Summer 2028
3 metrics
Cash and investments in marketable securities
$952.9 million
As of September 30, 2026
Expected cash runway
Into the third quarter of 2028
Nektar expects this, consistent with prior guidance
Initial ZENITH AD trial data readouts
Summer 2028
Phase 3 trials in atopic dermatitis
Key Terms
cash runway, Phase 3, atopic dermatitis, marketable securities
4 terms
cash runway financial
"expects that this cash balance will extend its cash runway"
Cash runway is the amount of time a company can continue operating using its available cash before needing additional funding or generating enough revenue. It’s like a countdown showing how long a business can keep running with its current funds. Knowing the cash runway helps investors assess the company's financial health and whether it has enough resources to reach its goals or needs to find more support soon.
Phase 3 medical
"Phase 3 ZENITH AD trials"
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
atopic dermatitis medical
"trials in atopic dermatitis"
A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.
marketable securities financial
"cash and investments in marketable securities"
Marketable securities are financial assets — such as publicly traded stocks, bonds, and short-term government bills — that a company can quickly sell for cash at a known price. Investors watch them because they show how much ready cash a company can access without selling core operations, like keeping money in a highly liquid savings account versus being tied up in a house, and they affect short-term risk, financial flexibility, and balance-sheet strength.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much cash and investments did NKTR report?
Nektar reported $952.9 million in cash and investments in marketable securities as of September 30, 2026.
How long does NKTR expect its cash runway to last?
Nektar expects its cash runway to extend into the third quarter of 2028, past initial data readouts from the Phase 3 ZENITH AD trials in atopic dermatitis in summer 2028.
AI-generated analysis. How Rhea-AI works. Not financial advice.
